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Abstract
The human low molecular weight protein tyrosine phosphatase (LMW-PTP) has been identified as a
target for inhibition as its overexpression leads to metastatic transformation and invasivity in several
human cancers such as breast, colon, bladder, and kidney. Extra precision docking with Glide on LMWPTP isoform B was used to virtually screen 1356 compounds from the National Cancer Institute (NCI)
diversity set II for new potential inhibitors. Twenty-one compounds identified as potential inhibitors by
in silico screening methods were acquired from NCI. The compounds were kinetically analyzed on LMWPTP isoform B to validate their selection as potential inhibitors. The best fit inhibition constants for the
selected compounds were determined from in vitro kinetic experiments. The results of the kinetic assay
and inhibition constants are reported and discussed.
Introduction
Post-translational phosphorylation of proteins is a reversible modification that is critical for control of
cellular functions. The phosphorylation of tyrosine residues is a ubiquitous control mechanism for
regulation and signaling in eukaryotes. The intricate regulation of these proteins is dynamically
controlled by phosphorylation of tyrosine side chains by protein tyrosine kinases (PTKs) and
dephosphorylation by protein tyrosine phosphatases (PTPs). The regulated activity of PTKs and PTPs are
vital to cell processes such as signaling, growth, migration, and gene transcription.1
PTPs can be divided into sub-groups including classical pTyr specific, dual specificity, Cdc25, and low
molecular weight phosphatases.2 These PTPs all share a common active site phosphate binding loop (PLoop) consisting of CX5R(S/T) but differ in otherwise in sequence and specificity. The low molecular
weight PTPs have emerged as novel drug targets for their involvement in metabolic and tumor
regulation.1
The human low molecular weight protein tyrosine phosphatase (LMW-PTP) exists in two active isoforms,
A and B, and two catalytically inactive variants, isoform C and SV3 (splicing variant 3). The two active
isoenzymes are made by alternate splicing of transcribed RNA causing isoform A to differ in a loop
comprised of amino acid residues 40-73 that adjacent to the catalytic site,.1,5 The variation determines
specificity for the isoenzymes.1
Human low molecular weight protein tyrosine phosphatase (LMW-PTP) is active downstream in the
signaling pathways of growth factors and has been linked to cellular transformation.2-5 LMW-PTP mRNA
and protein levels were significantly increased in human breast, colon, bladder, and kidney tumor
samples.6 Overexpression of LMW-PTP in tumor cells is enough to induce neoplasticity in
nontransformed cells.1 Additionally, high levels of LMW-PTP are generally prognostic of a more
aggressive cancer.1,8

The oncogenic potential of LMW-PTP is closely related to an endogenous substrate, the ephrin type A2
(EphA2) plasma membrane receptor.1 This EphA2 tyrosine kinase receptor activity is strongly associated
within human cancers, contributing to the invasivity of prostate, kidney, and lung cancers. The ligandindependent stimulation of EphA2 increases cellular migration and progression of tumors.7 The
overexpression of EphA2 is associated with increased expression of LMW-PTP which also regulates its
activity through dephosphorylation.1 When associated with EphA2, LMW-PTP is less available for
dephosphorylate p190Rho-Gap, which leads to weakened cell-matrix adhesion. This reduced activity on
the p190Rho-Gap leads to weakened cell-matrix adhesion.6 The Rho GTPases are instrumental in the
regulation of cytoskeletal reorganization driving translocation.7
It has been demonstrated that diverse molecules modulate the activity of LMW-PTP, including
flavonoids, quercetin and morin, adenine, and purines.9-12 Attempts to synthesize inhibitors of LMW-PTP
have been impeded by insufficient data about the inhibitor – protein interactions.13 Although a known
inhibitor of LMW-PTP, pyridoxal 5’-phosphate (PLP) displays the tight binding (Kis = 7.6 µM, pH 5)
necessary for good inhibition, it is also a necessary cofactor for other enzymes, and thus lacks the
specificity required.14 Two inhibitors for bovine-LMW-PTP (which has 94% sequence homology with the
human enzyme), ptp-043 and ptp-194, have similar Kis values ( 11 ± 2 µM and 9 ± 3 µM respectively).15
These compounds were discovered through virtual screening of the Chem Div collection (version 2004)
via Autodock 3.0.15 The search for novel inhibitors of LMW-PTP has been aided by virtual screening of
compound libraries.8,15,16
To increase the speed of discovery, the publicly available National Cancer Institute’s (NCI) Diversity Set II
was virtually screened in silico using Glide.8 Those compounds which showed the highest in silico
binding affinity were obtained from the NCI/DTP Open Chemical Repository, and tested for inhibitory
activity in vitro with LMW-PTP isoform B. The most promising target compounds will be used as scaffolds
for optimizing inhibition.
Results and Discussion
The in silico screening of the National Cancer Institute’s Diversity Set II led to the selection of 24
compounds for in vitro analysis. Given the small amount of sample (5 mg), initial analysis of inhibition
was conducted at a single final inhibitor concentration (450 µM) (single point assay, see supplemental
materials) Promising candidates were then tested in either a multiple-point micro or macro assay,
depending on the amount of inhibitor available. For solubility reasons, two compounds (639174 and
62840) were tested at a lower single concentration but showed little inhibition in micro assays ( Ki =538
µM and 3.30 mM, respectively). Nine compounds (107022, 76988, 182400, 156563, 38042, 82560,
77468, 19803, and 7578) showed inhibition constants less than 450 µM at pH 5.5. These were purchased
from Sigma-Aldrich and were then tested further. The results of single point test, micro and macro
assays are summarized in table 1.
Five of the inhibitors (107022, 76988, 182400, 156563, and 38042) showed strong inhibition, with (Ki
values less than 100 µM.. The structures of these inhibitors are shown in Figure 1. Compounds 107022
(Kis 10.8 ± 1.0 µM) and 76988 had and (18.8 ± 2.1 µM) had inhibition constants similar to that of PLP (Kis
=7.6 ± 1.8 µM). These compounds interacted with the P-loop through highly oxygenated ring systems

(figures 2 and 3 respectively). Two compounds (156563 and 38042), interacted with the P-loop through
an anionic carboxylate (figures 4 and 5). A third compound with the anionic carboxylate is predicted to
place the functional group distal to the active site, and direct chlorine atoms toward it instead (figure 6).
Two of these (182400 and 38042) gave better fits to the kinetic data as mixed inhibitors. It should be
noted that although some of our most effective inhibitors best fit competitive inhibition, others gave
best fits to noncompetitive inhibition (182400 and 38042) and uncompetitive inhibtion (77468). The
structure of compound 77468 docked into the active site is shown in figure 7 for comparison. The pose
in figure 7 shows that is possible for 77468 to bind to the protein while inorganic phosphate is still
covalently attached to the active site cysteine and effect inhibition by reducing the rate that phosphate
is cleaved by water. Inhibition models other than competitive (as displayed by 182400 and 38042) might
arise from different modes of binding of these inhibitors with LMW-PTP.
All of the top five inhibitors have rings which bind in the active site. The top two compounds, 107022
and 76988, are shown to use their highly hydroxylated rings to interact with Arg 18 in the P-loop and a
proximal Asn 50. The structure of 156563 shares similarity with NSC 45576 (Figure 1), which was
included in Diversity Set I and had an IC50 of 3.9 µM at pH 5. These two compounds exhibit similarities in
the constraint of the double bonded nitrogen and the oxygenated fused ring system in the active site. A
key difference between the two molecules is the type of interaction with the protein. 45576 uses a
sulfonate, while 156563 utilizes a carboxylic acid. The structure of 76988 resembles the flavonoids,
quercetin and morin, previously reported to activate and inhibit LMW-PTP respectively.
Conclusion
The in silico screening of the NCI Diversity Set II was conducted with Glide for LMW-PTP isoform B. The
potential inhibitors from the in silico screening were analyzed by in vitro kinetic assays. Nine of 24
(37.5%) selected screened inhibitors displayed Ki less than 450 µM, while five (20.8%) had Ki less than
100 µM. The compounds 107022 and 76988 have Ki values similar to that of PLP, a nonspecific cellular
inhibitor and as such might prove to be useful candidates for further investigation. The screening of
diversity set II has produced new scaffolds for optimization. Additional testing to gauge the specificity
of these new candidates for LMW-PTP would be useful.
Although the screening of Diversity Set II identified inhibitors for LMW-PTP with Ki less than 100 µM, the
screen also produced compounds which had Ki in the millimolar range. The origin of the wide range of
results is unclear but indicates that more information about small molecule interactions with LMW-PTP
is needed.
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Table1: Experimentally determined inhibition constants of compounds for isoform B.
Compound (NSC#)
107022
76988
182400*
156563
38042*
82560
77468**
19803
7578
140899
639174
91529
114436
50572
403379
81750
362639
146554
58-85-5#
134580
62840
4649-09-6#
205842
89720

Competitive
Kis (µM)
10.8 ± 1.0
18.8 ± 2.1

Uncompetitive
Kii (µM)

Mixed
Ki (µM)

26.0 ± 8.0
35.0 ± 6.7
33.5 ± 8.2
73.2 ± 29.2
108.2 ± 30.3
128.0 ± 29.9
121.1 ± 9.9
125.7 ± 23.1
161 ± 19
493
538
635
730
925
1.185x103
1.563x103
1.65x103
2.23x103
2.33x103 ± 0.33x103
2.78x103
3.30x103
7.19x103 ± 0.66x103
17.65x103
66.5x103 ± 39.3x103

*Best fit noncompetitive inhibition
**Best fit uncompetitive inhibition
#
CAS number, as no NSC number available
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Figure 1. A. Structures of inhibitors having Ki less than 100 µM. B. Uncompetitive inhibitor 77468. C.
Compound 45576, a previously reported inhibitor of LMW-PTP isoform B.

Figure 2. The best fit orientation of 107022 in the active site of 1XWW as predicted by Glide. Also shown
are the interactions with active site residues.

Figure 3. The best fit orientation of 76988 in the active site of 1XWW as predicted by Glide. Also shown
are the interactions with active site residues.

Figure 4. The best fit orientation of 156563 in the active site of 1XWW as predicted by Glide. Also shown
are the interactions with active site residues.

Figure 5. The best fit orientation of 38042 in the active site of 1XWW as predicted by Glide. The best fit
was mixed inhibition. Also shown are the interactions with active site residues.

Figure 6. The best fit orientation of 182400 in the active site of 1XWW as predicted by Glide. The best fit
was mixed inhibition. Also shown are the interactions with active site residues.

Figure 7. The best fit orientation of 77468 in the active site of 1XWW as predicted by Glide. The best fit
was uncompetitive. Also shown are the interactions with active site residues.
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Supplemental Materials
Experimental
Materials
Compounds with NSC numbers 38042, 205842, 639174, 50572, 114436, 146554, 182400, 140899,
76988, 134580, 81750, 156563, 62840, 82560, 77468, 7578, 91529, 107022, 403379, 19803, 362639
were obtained from the National Cancer Institute Developmental Therapeutics Program. P-nitrophenyl
phosphate was purchased from Research Organics. Compounds: 58-85-5, 4649-09-6, and 89720, as well
as all chemicals for solutions and preparation were purchased from Sigma-Aldrich unless otherwise
noted. All absorbance readings were read on a SpectraMax 340PC plate reader.
In silico screening parameters
The in silico screen for potential inhibitors was conducted using the National Cancer Institute’s (NCI)
Diversity Set II (http://dtp.nci.nih.gov/). Using Maestro from Schrödinger, the protein crystal structure
(1XWW) was imported from the Protein Data Bank and prepared using the Protein Preparation Wizard.
The deletion of waters beyond section is set to 0 and the protein reprocessed. Then the cocrystallized
glycerol and sulfate were removed and the pH range was set to 5.5 ± 2. The protein was refined with
exhaustive sampling and optimized. After optimization and deselecting the Hydrogens only option, the
protein was minimized. Using Glide, a receptor grid was generated that was centered on the active site
cysteine (Cys 12). The ligands were prepared using LigPrep with the force field MMFFs (a pH range of 5.5
± 2), Epik scores, and set to generate at most four per ligand. The docking was done using Glide, with the
receptor grid and prepared ligands. Epik state penalties were added, the screen was set to write out at
most 10 poses per ligand, and write out residue interaction scores for residues within 20 angstroms.
Ligands of interest were chosen based on the most negative docking scores and were then ordered from
NCI.
Preparation of LMW-PTP isoform B
LMW-PTP isoform B (PDB code: 1XWW) was made in E. Coli after transformation of competent cells with
a plasmid (provided by David Bernlohr, University of Minnesota) containing human PTP in fusion with
glutathione S-transferase under the control of the lac promoter as described.18 Fusion protein
expression was initiated with IPTG. The fusion protein was used for all kinetic assays; stock solution was
diluted two-fold in glycerol and stored as a liquid stock at -20°C.
Preparation of Solutions
A 1.0 M sodium acetate/acetic acid pH 5.5 buffer was prepared by dissolving 27.2 g sodium acetate in
200 mL of E-pure H2O; 30 mL of 1.0 M acetic acid (5.7 mL glacial acetic acid/100 mL) was added and the
pH adjusted accordingly. P-nitrophenyl phosphate (pnpp) solution (50.0 mM), was prepared by adding
0.928 g to 50 mL H2O. This stock solution was diluted to make substock solutions for enzyme assays of
10.0 mM, 5.0 mM, 2.5 mM, 1.25 mM, 0.800 mM, 0.625 mM, 0.500 mM, 0.374 mM, and 0.300 mM.
Potassium hydroxide solution, 0.5 M, was prepared using 14.03 g KOH in 500 mL of H2O. Pyridoxal 5’phosphate (PLP) solution, 0.263 mM, was prepared by dissolving 6.5 mg in 100 mL H2O and diluted 1/10
and 1/20 to 26.3 µM and 13.15 µM respectively. PLP and substrate solutions were stored in -20°C

freezer. Inhibitors utilized in the micro assay were dissolved in DMSO to create solutions that had an
approximate initial concentration of 18 mM.
Enzyme Assay
Enzyme assays used to determine kinetic parameters were conducted by adding specified amounts of a
stock 1.0 M sodium acetate/acetic acid buffer solution, H2O, and p-nitrophenyl phosphate (pnpp)at final
concentrations in the assay mixture of 2.0 mM, 1.0 mM, 0.5 mM, 0.25 mM, 0.16 mM, 0.125 mM, 0.10
mM, 0.075 mM, and 0.06 mM) to microcentrifuge tubes. Enzyme was added at time intervals to initiate
the reaction. After fifteen minutes, aliquots were removed to a 96-well plate containing KOH (0.5 M, 200
µL) to quench the reaction. A405 values were corrected for absorbance at each substrate concentration
in the absence of enzyme.
The appropriate enzyme dilution was determined in advance by making serial dilutions of the enzyme
(glycerol stock stored at -200C) and using the dilution which gave under specified test conditions an A405
of 0.120 in the plate reader. This dilution, used in all further assays, gave linear changes in concentration
of product over the time course chosen for inhibition studies, ensuring that quenched single point
absorbance values reflected the initial rates. Initial velocities were also directly proportional to enzyme
concentration, indicating the validity of the enzyme assay.
Validation of the enzyme assay was also conducted using PLP as a known inhibitor. PLP in our assays
was determined to be a competitive inhibitor with a Kis of 3.73 ± 0.39 µM, in accord with published
values. Enzyme assays 2.5% DMSO did not affect the assay results, showing that DMSO used to dissolve
the inhibitors had no effect on the enzyme assay. The activity of the glycerol enzyme stock was
measured daily as a quality control measure. Activity varied minimally and randomly over a several
month period.
Scaled Enzyme Assays:
Given the small amount of sample received from NCI, several different sets of assay conditions were
used to determine if the samples inhibited the enzyme (single point assay) and then to model the
inhibition and determine kinetic parameters (macro and micro assays). These include single point,
macro, and mini assays.
For the single point assay (conducted at one substrate concentration), duplicate reactions (Vfinal = 100
µL) containing inhibitor (18 – 0.36 mM, 2.5 µL), H2O (62.5 µL), acetic acid/acetate buffer solution (1.0 M,
5 µL), and pnpp (1.25 mM, 20 µL) were performed. At 30 second intervals, enzyme (10 µL) diluted in 1.0
M acetic acid/acetate buffer solution was added and allowed to react for 15 minutes. The reaction was
quenched by adding KOH (0.5 M, 150 µL) to the reaction mixture and 240 µL of the quenched reaction
mixtures were added to a 96-well plate for analysis.
The macro assay was used for compounds purchased from Sigma. The reactions mixtures (Vfinal = 500 µL)
contained acetic acid/acetate buffer solution (1.0 M, 50 µL), H2O (330 µL) , varying concentrations of
pnpp ( 100 µL) in the absence of inhibitor (330 µL water) and presence of two different fixed
concentrations of inhibitor (0.5 mM to 10.0 mM, 330 µL) whose concentrations were determined by the

single point assay. Measurements in the presence and absence of inhibitors were done in the same
assay. At 30 second intervals, enzyme (20 µl) was added to the reaction mixture which was allowed to
react for 15 minutes. The reaction was quenched by removing 100 µL of the reaction mixture to a 96well plate containing 150 µL of 0.5 M KOH.
The micro assay was used for compounds received from NCI after the single point test. The reaction
mixture (Vfinal = 100 µL) contained acetic acid/acetate buffer (1.0 M, 5 µL), H2O (62.5 µL), varying
concentrations of pnpp, and inhibitor (18.0 to 0.36mM, 2.5µL). Inhibition analysis was conducted
simultaneously with two different concentrations of inhibitor based on calculations from the single point
test. Measurements in the presence and absence of inhibitors were done in the same assay. At 30
second intervals, enzyme (10 µl) was added to the reaction mixture which was allowed to react for 15
minutes. The reaction was quenched by removing 100 µL of the reaction mixture to a 96-well plate
containing 150 µL of 0.5 M KOH.
Analysis using Visual Enzymics©
The inhibition constants (Kix) were calculated using Visual Enzymics through the IgorPro interface using
the one substrate one inhibitor section of the program. In the data page, the concentration (mM) of the
substrates and inhibitor in the reaction mixture were entered along with the velocity of the reaction.
The standard deviation and mask were set to 1. A405 values were converted to molarity units using an
extinction coefficient and path length for the plate. The data was fit to the equations for competitive,
uncompetitive, and mixed inhibition models.

